Clinical trials
Phase 4 Overweight trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
31 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 2 |
| 2008 | 1 |
| 2009 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 18 |
| Terminated | 4 |
| Recruiting | 3 |
| Not yet recruiting | 2 |
| Unknown status | 1 |
| Enrolling by invitation | 1 |
| Suspended | 1 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Eisai Inc. | 2 |
| Eli Lilly and Company | 2 |
| University of Pennsylvania | 2 |
| Beth Israel Deaconess Medical Center | 1 |
| Brigham and Women's Hospital | 1 |
| Columbia University | 1 |
| Gila Therapeutics, Inc. | 1 |
| GlaxoSmithKline | 1 |
| Jing Luo | 1 |
| Jody Dushay | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Obesity | 31 |
| Overweight | 31 |
| Weight Loss | 8 |
| Diabetes Mellitus, Type 2 | 7 |
| Prediabetic State | 4 |
| Body Weight | 3 |
| Body Weight Changes | 2 |
| Cardiovascular Diseases | 2 |
| Diabetes Mellitus | 2 |
| Metabolic Syndrome | 2 |
Trials
Showing 1 to 25 of 31. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.